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Comparable and Robust Immune Reconstitution after
HLA-Haploidentical or HLA-Matched Allogeneic
Transplantation (BMT) Utilizing Posttransplantation
Cyclophosphamide
Shannon R. McCurdy 1, Ante Vulic 1, Heather J. Symons 1,
Andrea M. Towlerton 2, Ben C. Valdez 3, Richard J. Jones 4,
Ephraim J. Fuchs 1, Paul V. O’Donnell 2, Edus H. Warren 2,
Christopher G. Kanakry 1, Leo Luznik 1. 1 Department of
Oncology, The Johns Hopkins University School of Medicine,
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Cancer Center, Houston, TX; 4 Department of Oncology, The
Johns Hopkins University, Baltimore, MDBackground: Posttransplantation cyclophosphamide (PTCy)
limits severe acute and chronic graft-versus-host disease
(GVHD) and facilitates engraftment, permitting HLA-
matched donor (MD) BMT without additional GVHD pro-
phylaxis and the safe performance of HLA-haploidentical
(haplo) BMT. Low rates of transplant related mortality,
infection, and post-transplant lymphoproliferative disorders
(PTLD) support that PTCy based immunosuppression allows
favorable immune recovery. However limited data exist
regarding immune reconstitution after haplo or MD BMT
utilizing PTCy.
Methods: We assessed immune recovery in 71 patients
undergoing myeloablative (MA) haplo BMT with PTCy
(50mg/kg on days +3 and +4), mycophenolate mofetil (MMF)
(days +5-35), and tacrolimus (days +5-180) as GVHD pro-
phylaxis and 73 patients undergoing MA MD BMT with PTCy
as sole GVHD prophylaxis. Flow cytometric immunopheno-
typing was performed on peripheral blood samples collected
serially at predetermined time points.
Results: Immune reconstitution was not statistically
different after HLA-matched related and HLA-matched
unrelated BMT; therefore these groups are reported together.
By 1 year after haplo and MD BMT, median ALCs were in the
normal range (1100-4800 cells/ml) and B-cell counts were
higher than those in normal donors. NK cells reached
normal donor numbers by 6 months. In patients without
GVHD, NK recovery was rapid, reaching normal donor
levels at 2-3months. Results were similar afterMD and haplo
BMT. However, CD4+ and CD8+ T-cell counts at 1 month
were statistically signiﬁcantly lower after haplo BMT
(p<0.0001 for both). At 1 year median CD4+ T-cell counts
were 227 and 286 after MD and haplo BMT, respectively.
Both values were signiﬁcantly lower than median donor
counts (632, p<0.0001). Median CD8+ T-cells at 6 months
and 1 year were not signiﬁcantly different when compared
with normal donors. However, there was a trend towards
lower total CD8+ T-cell counts at all time points after haplo
compared with MD BMT. Phenotypic effector memory (EM)
and terminally differentiated effector memory T-cells
(TEMRAs), particularly within the CD8+ fraction, recovered
rapidly after haplo orMD BMT. Yet, phenotypically naïve cells
remained low throughout the ﬁrst post-BMT year. Consistent
with our prior reports, Tregs comprised a larger portion of
CD4+ T-cells after MD or haplo BMT compared with donor
patterns (p<0.0001).
Conclusion: Haplo and MD BMT led to comparable
reconstitution of NK and B-cells; however CD4+ and CD8+
T-cell recovery lags early after haplo BMT. This delay is likely
attributable to the addition of MMF and tacrolimus, whichmay be mitigated by discontinuation of MMF at Day 35,
resulting in equivalent CD4+ T-cell and CD8+ T-cell counts by
3 and 6 months, respectively. Ultimately, excellent immune
reconstitution by 1 year supports the low rates of PTLD and
infectious deaths after haplo or MD BMT with PTCy.57
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CD4+FoxP3+ regulatory T cells (Treg) adoptive transfer
has proved to be an effective treatment for GVHD prevention
in several studies. Treg impact on immune reconstitution
and bone marrow engraftment after transplantation has
been less well studied.
We treated C57BL/6 FoxP3DTR mice with diphtheria toxin
(DT) resulting in a complete Treg ablation. Transplantation of
lethally irradiated (TBI 10 Gy) Treg depleted mice with
allogeneic (BALB/C or FVB/N) T-cell depleted bone marrow
(TCD BM) or puriﬁed hematopoietic stem cells (HSCs)
resulted in donor rejection or mixed chimerism (p < 0.01).
Treg depletion favored host CD4+ (p < 0.001), CD8+
(p< 0.01) and GR1+ cell persistence (p< 0.01) and delayed B
cell reconstitution (p < 0.001). Transfer of in vitro activated
with anti-CD3/CD28 beads and IL-2 Treg to DT treated
mice rescued engraftment (p < 0.01) and boosted B cell
reconstitution (p < 0.001).
Syngeneic transplanted Treg depleted mice engrafted but
had markedly delayed B cell reconstitution (p < 0.01) thus
Treg promote donor B cell differentiation in manner not
dependent upon alloreactivity. FACS analysis of bonemarrow
cells of these mice showed higher numbers of donor Lin-
Sca1+cKit+ HSCs (p < 0.05) and donor Lin-Sca1+cKit+Flt3+
lymphoid progenitors (p < 0.05) while B220+IgM-
CD19+cKit+ Pro-B cells (p < 0.05) and total CD19+ cells
(p< 0.01) were reduced demonstrating a block of maturation
in the early phases of B cell differentiation. IL-7 production
was reduced after Treg depletion (p < 0.05) suggesting that
Treg control B cell differentiation through an IL-7 dependent
mechanism. Confocal microscopic analysis of femurs after
transplantation demonstrated that Treg localize near the
endosteum (p < 0.0001) co-located with donor B220+ B cell
clusters and gather in the epiphyseal areas where donor
HSCs were mainly detectable suggesting that Treg act as an
immunological barrier for HSCs and B cell progenitors,
providing a protective niche.
Adoptive transfer of in vitro activated Treg induced B cell
reconstitution (p < 0.01) in non irradiated immune deﬁcient
BALB/C rag2-/-gc-/- mice that received allogeneic TCD BM.
Higher numbers of Pro-B cells (p < 0.05) and total CD19+
cells (p< 0.05) were found in the bonemarrow of these mice
with reduced levels of inﬂammatory cytokines such as INFg,
IL-12, IL-13, IL-1b, CXCR-9 and CXCR-10 and increased levels
of IL-7 and VEGF.
In conclusion, our ﬁndings indicate that Treg act as a key
regulator of B cell differentiation promoting production of
mature B cells through an IL-7 mediated mechanism that is
not dependent on alloantigen recognition. Our data suggest
that Treg play a role in building the donor HSC and B cell
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S72precursor niche. Finally, Treg adoptive transfer enhances B
cell reconstitution and induces tolerance to bone marrow
grafts even in the absence of conditioning providing a new
tool for clinical translation especially in childrenwith SCID or
hemoglobinopathies.LATE EFFECTS/QUALITY OF LIFE
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Background: Hematopoietic cell transplantation (HCT) is a
resource-intensive therapy. The economic costs to the
medical system have been well-described; however,
few studies have prospectively assessed the ﬁnancial
consequences of HCT for patients and their families.
Methods: We report preliminary data from a prospective
study of ﬁnancial hardship related to HCT. We mailed a
41-item questionnaire to adult patients approximately six
months post-allogeneic or autologous HCT at three sites
(Dana-Farber Cancer Institute [DFCI], Roswell Park Cancer
Institute, and Mayo Clinic Arizona). The questionnaire was
developed with input from a focus group of HCT nurses and
social workers, and underwent formal cognitive debrieﬁng
with HCT patients. HCT-related clinical outcomes associated
with hardship will be assessed at one year. We present the
ﬁnancial experience of the ﬁrst cohort of DFCI patients.
Results: As of October 1, 2014, of 174 surveys mailed, 124 had
been received (71%). Patients were a median of 174 days
post-HCT. The mean age was 57.6 years, 49% had had an
allogeneic transplant, 95% were white, 75% were married,
24% had at least one child at home, 52% were currently
working at least part-time or taking a leave of absence, and
46% had at least a bachelor’s degree. Patients came from 10
states; the top three were MA (45%), ME (14%) and NY (13%).
Compared to before transplant, 48% reported a decline in
monthly household income. Nearly half (48%) were also only
somewhat, slightly or not at all satisﬁed with their present
ﬁnancial situation, and 41% reported somewhat, moderate or
extreme difﬁculty in making bill payments. About one out of
ﬁve (21%) reported substantial hardship, deﬁned as not
having enough money at the end of the month, and 52.4%
(95% CI [43.5, 61.3]) reported either unsatisfactory income,
difﬁculty making payments, or substantial hardship.
Transplant type, gender, age, race, employment and college
degree were not signiﬁcantly associated with substantial
hardship; however, being unmarried (p< .03) and lower
income level (p<.02) were. Patients reported several
ﬁnancial coping strategies post-HCT (see table), which




Percent of all respondents 47% 43%
Odds ratio for substantial
hardship vs. other [95% CI]
6.4 [ 2.2, 18.7] 3.5 [ 1.4, 8.9]Conclusions: The majority of HCT patients face ﬁnancial
difﬁculties, particularly those who are not married or have
more limited income. Coping strategies vary, although
spending on prescription medicines is largely preserved.
Several strategies are much more prevalent among those
with substantial hardship. The ultimate effects of ﬁnancial
burden on HCT outcomes remain to be demonstrated.59
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Background: Approximately 10% of older (65y) individuals
in the general population demonstrate frailty (Collard RM et
al. J Am Geriatr Soc. 2012;60:1487-92). HCT recipients are at
risk for accelerated aging, given the high-intensity
therapeutic exposures and excessive burden of morbidity
after HCT. We examined the prevalence and predictors of
frailty in elderly (65y) HCT survivors.
Methods: Participants included 276 older HCT survivors
(median age at study participation: 70 y (65-84), who had
undergone HCT (allogeneic: n¼83, autologous: n¼196)
between 1985-2010. Median time from HCT was 8.9y
(3.7-29.1). Following well established survey-based screening
tools for frailty (Pialoux T et al. Geriatr Gerontol Int.
2012;12:189-97), all participants completed a self-report
survey that included questions pertaining to: low leanmuscle
mass, self-reported exhaustion, low energy expenditure, slow
walking speed, and muscle weakness. Prefrailty included 2,
while frailty included 3 conditions.
Results: The prevalence of prefrailty and frailty was 28% and
13%, respectively.Predictors of pre-frailty and/or frailty
After adjusting for age at enrollment, sex, race, education
and employment status, survivors with low income (annual
household income <$50,000/annual personal income
<$20,000) were 3.2 times more likely to report pre-frailty
and/or frailty (OR¼3.2, 1.5-6.9, p¼0.003); furthermore,
allogeneic HCT survivors with a history of cGvHD were 2.7
times more likely to report pre-frailty and/or frailty (OR¼2.7,




Cut back on prescribed
medicine
24% 59% 5%
7.9 [ 3.0, 20.7] 7.2 [2.0, 25.6] 8.4 [1.4, 48.6]
